ID   MCL1_HUMAN              Reviewed;         350 AA.
AC   Q07820; B2R6B2; D3DV03; D3DV04; Q9HD91; Q9NRQ3; Q9NRQ4; Q9UHR7;
AC   Q9UHR8; Q9UHR9; Q9UNJ1;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   06-DEC-2005, sequence version 3.
DT   22-JUL-2015, entry version 166.
DE   RecName: Full=Induced myeloid leukemia cell differentiation protein Mcl-1;
DE   AltName: Full=Bcl-2-like protein 3;
DE            Short=Bcl2-L-3;
DE   AltName: Full=Bcl-2-related protein EAT/mcl1;
DE   AltName: Full=mcl1/EAT;
GN   Name=MCL1; Synonyms=BCL2L3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASP-173.
RC   TISSUE=Myeloid leukemia cell;
RX   PubMed=7682708; DOI=10.1073/pnas.90.8.3516;
RA   Kozopas K.M., Yang T., Buchan H.L., Zhou P., Craig R.W.;
RT   "MCL1, a gene expressed in programmed myeloid cell differentiation,
RT   has sequence similarity to BCL2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:3516-3520(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INDUCTION.
RX   PubMed=8790944;
RA   Umezawa A., Maruyama T., Inazawa J., Imai S., Takano T., Hata J.;
RT   "Induction of mcl1/EAT, Bcl-2 related gene, by retinoic acid or heat
RT   shock in the human embryonal carcinoma cells, NCR-G3.";
RL   Cell Struct. Funct. 21:143-150(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11130466; DOI=10.1007/PL00000728;
RA   Akgul C., Turner P.C., White M.R.H., Edwards S.W.;
RT   "Functional analysis of the human MCL-1 gene.";
RL   Cell. Mol. Life Sci. 57:684-691(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 2), VARIANT ASP-173,
RP   AND FUNCTION.
RC   TISSUE=Myeloid leukemia cell, and Neuroblastoma;
RX   PubMed=10766760; DOI=10.1074/jbc.M909572199;
RA   Bingle C.D., Craig R.W., Swales B.M., Singleton V., Zhou P.,
RA   Whyte M.K.B.;
RT   "Exon skipping in Mcl-1 results in a Bcl-2 homology domain 3 only gene
RT   product that promotes cell death.";
RL   J. Biol. Chem. 275:22136-22146(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND INTERACTION WITH
RP   BAX; BAK1; BCL2L11 AND BETWEEN ISOFORMS 1 AND 2.
RX   PubMed=10837489; DOI=10.1074/jbc.M909826199;
RA   Bae J., Leo C.P., Hsu S.Y., Hsueh A.J.W.;
RT   "MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member
RT   MCL-1, encodes a proapoptotic protein possessing only the BH3
RT   domain.";
RL   J. Biol. Chem. 275:25255-25261(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   VAL-227.
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-227.
RG   NIEHS SNPs program;
RL   Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Mammary gland, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 182-289 (ISOFORM 1), AND VARIANT
RP   VAL-227.
RC   TISSUE=Ewing sarcoma;
RX   PubMed=10634649; DOI=10.1016/S0145-2126(99)00137-X;
RA   Okita H., Umezawa A., Fukuma M., Hata J.;
RT   "Acute myeloid leukemia possessing jumping translocation is related to
RT   highly elevated levels of EAT/mcl-1, a Bcl-2 related gene with anti-
RT   apoptotic functions.";
RL   Leuk. Res. 24:73-77(2000).
RN   [13]
RP   PROTEIN SEQUENCE OF N-TERMINUS OF FRAGMENTS OBTAINED BY CASPASE
RP   CLEAVAGE, AND MUTAGENESIS OF ASP-127 AND ASP-157.
RX   PubMed=15122313; DOI=10.1038/sj.onc.1207648;
RA   Michels J., O'Neill J.W., Dallman C.L., Mouzakiti A., Habens F.,
RA   Brimmell M., Zhang K.Y.J., Craig R.W., Marcusson E.G., Johnson P.W.M.,
RA   Packham G.;
RT   "Mcl-1 is required for Akata6 B-lymphoma cell survival and is
RT   converted to a cell death molecule by efficient caspase-mediated
RT   cleavage.";
RL   Oncogene 23:4818-4827(2004).
RN   [14]
RP   INDUCTION.
RX   PubMed=9671497;
RA   Chao J.-R., Wang J.-M., Lee S.-F., Peng H.-W., Lin Y.-H., Chou C.-H.,
RA   Li J.-C., Huang H.-M., Chou C.-K., Kuo M.-L., Yen J.J.-Y.,
RA   Yang-Yen H.-F.;
RT   "Mcl-1 is an immediate-early gene activated by the granulocyte-
RT   macrophage colony-stimulating factor (GM-CSF) signaling pathway and is
RT   one component of the GM-CSF viability response.";
RL   Mol. Cell. Biol. 18:4883-4898(1998).
RN   [15]
RP   INTERACTION WITH TPT1, AND SUBCELLULAR LOCATION.
RX   PubMed=12149273; DOI=10.1074/jbc.M207413200;
RA   Zhang D., Li F., Weidner D., Mnjoyan Z.H., Fujise K.;
RT   "Physical and functional interaction between myeloid cell leukemia 1
RT   protein (MCL1) and fortilin. The potential role of MCL1 as a fortilin
RT   chaperone.";
RL   J. Biol. Chem. 277:37430-37438(2002).
RN   [16]
RP   PHOSPHORYLATION AT SER-121 AND THR-163.
RX   PubMed=12223490; DOI=10.1074/jbc.M207951200;
RA   Inoshita S., Takeda K., Hatai T., Terada Y., Sano M., Hata J.,
RA   Umezawa A., Ichijo H.;
RT   "Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in
RT   response to oxidative stress.";
RL   J. Biol. Chem. 277:43730-43734(2002).
RN   [17]
RP   INTERACTION WITH BAK, AND SUBCELLULAR LOCATION.
RX   PubMed=15077116; DOI=10.1038/ncb1123;
RA   Leu J.I.-J., Dumont P., Hafey M., Murphy M.E., George D.L.;
RT   "Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1
RT   complex.";
RL   Nat. Cell Biol. 6:443-450(2004).
RN   [18]
RP   PHOSPHORYLATION AT THR-163, AND MUTAGENESIS OF SER-162 AND THR-163.
RX   PubMed=15241487; DOI=10.1038/sj.onc.1207692;
RA   Domina A.M., Vrana J.A., Gregory M.A., Hann S.R., Craig R.W.;
RT   "MCL1 is phosphorylated in the PEST region and stabilized upon ERK
RT   activation in viable cells, and at additional sites with cytotoxic
RT   okadaic acid or taxol.";
RL   Oncogene 23:5301-5315(2004).
RN   [19]
RP   UBIQUITINATION, AND MUTAGENESIS OF LYS-5; LYS-40; LYS-136; LYS-194;
RP   LYS-197; LYS-208 AND LYS-234.
RX   PubMed=15989957; DOI=10.1016/j.cell.2005.06.009;
RA   Zhong Q., Gao W., Du F., Wang X.;
RT   "Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the
RT   polyubiquitination of Mcl-1 and regulates apoptosis.";
RL   Cell 121:1085-1095(2005).
RN   [20]
RP   FUNCTION AS INHIBITOR OF APOPTOSIS, PHOSPHORYLATION AT SER-159 BY
RP   GSK3-ALPHA AND GSK3-BETA, UBIQUITINATION, AND MUTAGENESIS OF SER-159.
RX   PubMed=16543145; DOI=10.1016/j.molcel.2006.02.009;
RA   Maurer U., Charvet C., Wagman A.S., Dejardin E., Green D.R.;
RT   "Glycogen synthase kinase-3 regulates mitochondrial outer membrane
RT   permeabilization and apoptosis by destabilization of MCL-1.";
RL   Mol. Cell 21:749-760(2006).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-162 AND THR-163, AND
RP   MUTAGENESIS OF SER-162.
RX   PubMed=23024798; DOI=10.1371/journal.pone.0045088;
RA   Thomas L.W., Lam C., Clark R.E., White M.R., Spiller D.G., Moots R.J.,
RA   Edwards S.W.;
RT   "Serine 162, an essential residue for the mitochondrial localization,
RT   stability and anti-apoptotic function of Mcl-1.";
RL   PLoS ONE 7:E45088-E45088(2012).
RN   [23]
RP   INTERACTION WITH BOP/C22ORF29.
RX   PubMed=23055042; DOI=10.1007/s13238-012-2069-7;
RA   Zhang X., Weng C., Li Y., Wang X., Jiang C., Li X., Xu Y., Chen Q.,
RA   Pan L., Tang H.;
RT   "Human Bop is a novel BH3-only member of the Bcl-2 protein family.";
RL   Protein Cell 3:790-801(2012).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 151-307 IN COMPLEXES WITH
RP   PMAIP1 AND BCL2L11.
RX   PubMed=17389404; DOI=10.1073/pnas.0701297104;
RA   Czabotar P.E., Lee E.F., van Delft M.F., Day C.L., Smith B.J.,
RA   Huang D.C.S., Fairlie W.D., Hinds M.G., Colman P.M.;
RT   "Structural insights into the degradation of Mcl-1 induced by BH3
RT   domains.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:6217-6222(2007).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 172-327 IN COMPLEX WITH
RP   BCL2L11.
RX   PubMed=20562877; DOI=10.1038/nchembio.391;
RA   Stewart M.L., Fire E., Keating A.E., Walensky L.D.;
RT   "The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis
RT   sensitizer.";
RL   Nat. Chem. Biol. 6:595-601(2010).
RN   [26]
RP   VARIANT [LARGE SCALE ANALYSIS] LEU-231.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J.,
RA   Heath S., Shannon W.D., Nagarajan R., Walter M.J., Link D.C.,
RA   Graubert T.A., DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
CC   -!- FUNCTION: Involved in the regulation of apoptosis versus cell
CC       survival, and in the maintenance of viability but not of
CC       proliferation. Mediates its effects by interactions with a number
CC       of other regulators of apoptosis. Isoform 1 inhibits apoptosis.
CC       Isoform 2 promotes apoptosis. {ECO:0000269|PubMed:10766760,
CC       ECO:0000269|PubMed:16543145}.
CC   -!- SUBUNIT: Interacts with HIF3A (via C-terminus domain) (By
CC       similarity). Interacts with BAD, BOK, BIK and BFM. Interacts with
CC       PMAIP1. Isoform 1 interacts with BAX, BAK1, TPT1 and BCL2L11.
CC       Heterodimer of isoform 1 and isoform 2. Homodimers of isoform 1 or
CC       isoform 2 are not detected. Isoform 2 does not interact with pro-
CC       apoptotic BCL2-related proteins. Interacts with BOP. Interacts
CC       with BCL2L11; may sequester BCL2L11 to prevent its pro-apoptotic
CC       activity. {ECO:0000250|UniProtKB:P97287,
CC       ECO:0000269|PubMed:10837489, ECO:0000269|PubMed:12149273,
CC       ECO:0000269|PubMed:15077116, ECO:0000269|PubMed:20562877,
CC       ECO:0000269|PubMed:23055042}.
CC   -!- INTERACTION:
CC       Q91AU0:- (xeno); NbExp=2; IntAct=EBI-1003422, EBI-9657017;
CC       Q16611:BAK1; NbExp=10; IntAct=EBI-1003422, EBI-519866;
CC       Q07812:BAX; NbExp=6; IntAct=EBI-1003422, EBI-516580;
CC       Q9BXH1:BBC3; NbExp=3; IntAct=EBI-1003422, EBI-519884;
CC       O43521:BCL2L11; NbExp=11; IntAct=EBI-1003422, EBI-526406;
CC       Q14457:BECN1; NbExp=2; IntAct=EBI-1003422, EBI-949378;
CC       Q03135:CAV1; NbExp=3; IntAct=EBI-1003422, EBI-603614;
CC       P49817:Cav1 (xeno); NbExp=3; IntAct=EBI-1003422, EBI-1161338;
CC       Q13794:PMAIP1; NbExp=5; IntAct=EBI-1003422, EBI-707392;
CC       Q9JM54:Pmaip1 (xeno); NbExp=2; IntAct=EBI-1003422, EBI-709183;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Single-pass membrane
CC       protein {ECO:0000305}. Cytoplasm. Mitochondrion. Nucleus,
CC       nucleoplasm. Note=Cytoplasmic, associated with mitochondria.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=MCL1L, MCL-1L;
CC         IsoId=Q07820-1; Sequence=Displayed;
CC       Name=2; Synonyms=Delta S, MCL-1S, TM;
CC         IsoId=Q07820-2; Sequence=VSP_000532, VSP_000533;
CC   -!- INDUCTION: Expression increases early during phorbol ester-induced
CC       differentiation along the monocyte/macrophage pathway in myeloid
CC       leukemia cell line ML-1. Rapidly up-regulated by CSF2 in ML-1
CC       cells. Up-regulated by heat shock-induced differentiation.
CC       Expression increases early during retinoic acid-induced
CC       differentiation. {ECO:0000269|PubMed:8790944,
CC       ECO:0000269|PubMed:9671497}.
CC   -!- PTM: Cleaved by CASP3 during apoptosis. In intact cells cleavage
CC       occurs preferentially after Asp-127, yielding a pro-apoptotic 28
CC       kDa C-terminal fragment.
CC   -!- PTM: Rapidly degraded in the absence of phosphorylation on Thr-163
CC       in the PEST region. {ECO:0000269|PubMed:12223490,
CC       ECO:0000269|PubMed:15241487, ECO:0000269|PubMed:23024798}.
CC   -!- PTM: Phosphorylated on Ser-159, by GSK3, in response to
CC       IL3/interleukin-3 withdrawal. Phosphorylation at Ser-159 induces
CC       ubiquitination and proteasomal degradation, abrogating the anti-
CC       apoptotic activity. Treatment with taxol or okadaic acid induces
CC       phosphorylation on additional sites.
CC       {ECO:0000269|PubMed:16543145}.
CC   -!- PTM: Ubiquitinated. Ubiquitination is induced by phosphorylation
CC       at Ser-159. {ECO:0000269|PubMed:16543145}.
CC   -!- SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/mcl1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L08246; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AF118124; AAD13299.1; -; mRNA.
DR   EMBL; AF147742; AAF74821.1; -; Genomic_DNA.
DR   EMBL; AF198614; AAF64255.1; -; Genomic_DNA.
DR   EMBL; AF198614; AAF64256.1; -; Genomic_DNA.
DR   EMBL; AF162677; AAG00896.1; -; Genomic_DNA.
DR   EMBL; AF162676; AAG00896.1; JOINED; Genomic_DNA.
DR   EMBL; AF203373; AAG00904.1; -; mRNA.
DR   EMBL; BT006640; AAP35286.1; -; mRNA.
DR   EMBL; AK312508; BAG35409.1; -; mRNA.
DR   EMBL; DQ088966; AAY68220.1; -; Genomic_DNA.
DR   EMBL; AL356356; CAI15503.1; -; Genomic_DNA.
DR   EMBL; AL356356; CAI15504.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53538.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53539.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53540.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53541.1; -; Genomic_DNA.
DR   EMBL; BC017197; AAH17197.1; -; mRNA.
DR   EMBL; BC071897; AAH71897.1; -; mRNA.
DR   EMBL; BC107735; AAI07736.1; -; mRNA.
DR   EMBL; AF118276; AAF15309.1; -; mRNA.
DR   EMBL; AF118277; AAF15310.1; -; mRNA.
DR   EMBL; AF118278; AAF15311.1; -; mRNA.
DR   CCDS; CCDS956.1; -. [Q07820-2]
DR   CCDS; CCDS957.1; -. [Q07820-1]
DR   PIR; A47476; A47476.
DR   RefSeq; NP_001184249.1; NM_001197320.1.
DR   RefSeq; NP_068779.1; NM_021960.4. [Q07820-1]
DR   RefSeq; NP_877495.1; NM_182763.2. [Q07820-2]
DR   UniGene; Hs.632486; -.
DR   PDB; 2KBW; NMR; -; A=163-326.
DR   PDB; 2MHS; NMR; -; A=171-327.
DR   PDB; 2NL9; X-ray; 1.55 A; A=209-327.
DR   PDB; 2NLA; X-ray; 2.80 A; A=209-327.
DR   PDB; 2PQK; X-ray; 2.00 A; A=172-327.
DR   PDB; 3D7V; X-ray; 2.03 A; A=209-327.
DR   PDB; 3IO9; X-ray; 2.40 A; A=209-327.
DR   PDB; 3KJ0; X-ray; 1.70 A; A=172-327.
DR   PDB; 3KJ1; X-ray; 1.94 A; A=172-327.
DR   PDB; 3KJ2; X-ray; 2.35 A; A=172-327.
DR   PDB; 3KZ0; X-ray; 2.35 A; A/B=172-327.
DR   PDB; 3MK8; X-ray; 2.32 A; A=172-327, B=208-228.
DR   PDB; 3PK1; X-ray; 2.49 A; A/C=174-326.
DR   PDB; 3TWU; X-ray; 1.80 A; B=73-88.
DR   PDB; 3WIX; X-ray; 1.90 A; A/B/C/D=172-327.
DR   PDB; 3WIY; X-ray; 2.15 A; A/B/C/D/E/F=172-327.
DR   PDB; 4BPI; X-ray; 1.98 A; A=209-327.
DR   PDB; 4BPJ; X-ray; 1.60 A; A=209-327.
DR   PDB; 4HW2; X-ray; 2.80 A; A/B/C/D/E/F=172-323.
DR   PDB; 4HW3; X-ray; 2.40 A; A/B/C/D/E/F/G/H/I/J/K/L=172-323.
DR   PDB; 4HW4; X-ray; 1.53 A; A/B=172-327.
DR   PDB; 4OQ5; X-ray; 2.86 A; A/B/C/D/E/F=174-326.
DR   PDB; 4OQ6; X-ray; 1.81 A; A/B=174-326.
DR   PDB; 4WGI; X-ray; 1.85 A; A=173-321.
DR   PDB; 4WMR; X-ray; 1.70 A; A=173-321.
DR   PDB; 4WMS; X-ray; 1.90 A; A=174-321.
DR   PDB; 4WMT; X-ray; 2.35 A; A=174-321.
DR   PDB; 4WMU; X-ray; 1.55 A; A=174-321.
DR   PDB; 4WMV; X-ray; 2.40 A; A=174-321.
DR   PDB; 4WMW; X-ray; 1.90 A; A=174-321.
DR   PDB; 4WMX; X-ray; 2.00 A; A=174-321.
DR   PDB; 4ZBF; X-ray; 2.20 A; A/B/C/D/E/F/G/H/I/J/K/L=172-327.
DR   PDB; 4ZBI; X-ray; 2.50 A; A/B/C/D/E/F/G/H/I/J/K/L=172-327.
DR   PDBsum; 2KBW; -.
DR   PDBsum; 2MHS; -.
DR   PDBsum; 2NL9; -.
DR   PDBsum; 2NLA; -.
DR   PDBsum; 2PQK; -.
DR   PDBsum; 3D7V; -.
DR   PDBsum; 3IO9; -.
DR   PDBsum; 3KJ0; -.
DR   PDBsum; 3KJ1; -.
DR   PDBsum; 3KJ2; -.
DR   PDBsum; 3KZ0; -.
DR   PDBsum; 3MK8; -.
DR   PDBsum; 3PK1; -.
DR   PDBsum; 3TWU; -.
DR   PDBsum; 3WIX; -.
DR   PDBsum; 3WIY; -.
DR   PDBsum; 4BPI; -.
DR   PDBsum; 4BPJ; -.
DR   PDBsum; 4HW2; -.
DR   PDBsum; 4HW3; -.
DR   PDBsum; 4HW4; -.
DR   PDBsum; 4OQ5; -.
DR   PDBsum; 4OQ6; -.
DR   PDBsum; 4WGI; -.
DR   PDBsum; 4WMR; -.
DR   PDBsum; 4WMS; -.
DR   PDBsum; 4WMT; -.
DR   PDBsum; 4WMU; -.
DR   PDBsum; 4WMV; -.
DR   PDBsum; 4WMW; -.
DR   PDBsum; 4WMX; -.
DR   PDBsum; 4ZBF; -.
DR   PDBsum; 4ZBI; -.
DR   ProteinModelPortal; Q07820; -.
DR   SMR; Q07820; 133-324.
DR   BioGrid; 110338; 57.
DR   DIP; DIP-231N; -.
DR   IntAct; Q07820; 27.
DR   MINT; MINT-89669; -.
DR   STRING; 9606.ENSP00000358022; -.
DR   BindingDB; Q07820; -.
DR   ChEMBL; CHEMBL4361; -.
DR   PhosphoSite; Q07820; -.
DR   BioMuta; MCL1; -.
DR   DMDM; 83304396; -.
DR   MaxQB; Q07820; -.
DR   PaxDb; Q07820; -.
DR   PRIDE; Q07820; -.
DR   DNASU; 4170; -.
DR   Ensembl; ENST00000307940; ENSP00000309973; ENSG00000143384. [Q07820-2]
DR   Ensembl; ENST00000369026; ENSP00000358022; ENSG00000143384.
DR   GeneID; 4170; -.
DR   KEGG; hsa:4170; -.
DR   UCSC; uc001euz.3; human. [Q07820-1]
DR   UCSC; uc001eva.3; human. [Q07820-2]
DR   CTD; 4170; -.
DR   GeneCards; GC01M150547; -.
DR   HGNC; HGNC:6943; MCL1.
DR   HPA; CAB002781; -.
DR   HPA; CAB068195; -.
DR   HPA; HPA008455; -.
DR   HPA; HPA031125; -.
DR   MIM; 159552; gene.
DR   neXtProt; NX_Q07820; -.
DR   PharmGKB; PA30688; -.
DR   eggNOG; NOG282183; -.
DR   GeneTree; ENSGT00510000048923; -.
DR   HOVERGEN; HBG003527; -.
DR   InParanoid; Q07820; -.
DR   KO; K02539; -.
DR   OMA; AKDTKPM; -.
DR   OrthoDB; EOG7S2209; -.
DR   PhylomeDB; Q07820; -.
DR   TreeFam; TF315834; -.
DR   ChiTaRS; MCL1; human.
DR   EvolutionaryTrace; Q07820; -.
DR   GeneWiki; MCL1; -.
DR   GenomeRNAi; 4170; -.
DR   NextBio; 16422; -.
DR   PMAP-CutDB; Q07820; -.
DR   PRO; PR:Q07820; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; Q07820; -.
DR   CleanEx; HS_MCL1; -.
DR   ExpressionAtlas; Q07820; baseline and differential.
DR   Genevisible; Q07820; HS.
DR   GO; GO:0097136; C:Bcl-2 family protein complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; ISS:UniProtKB.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:Ensembl.
DR   GO; GO:0005741; C:mitochondrial outer membrane; TAS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0051434; F:BH3 domain binding; IPI:BHF-UCL.
DR   GO; GO:0015266; F:protein channel activity; TAS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IBA:GO_Central.
DR   GO; GO:0008637; P:apoptotic mitochondrial changes; IEA:Ensembl.
DR   GO; GO:0001709; P:cell fate determination; NAS:UniProtKB.
DR   GO; GO:0019725; P:cellular homeostasis; NAS:UniProtKB.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IMP:UniProtKB.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IBA:GO_Central.
DR   GO; GO:0007275; P:multicellular organismal development; IEA:UniProtKB-KW.
DR   GO; GO:2000811; P:negative regulation of anoikis; IMP:UniProtKB.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:UniProtKB.
DR   GO; GO:2001243; P:negative regulation of intrinsic apoptotic signaling pathway; IBA:GO_Central.
DR   GO; GO:1903378; P:positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0071806; P:protein transmembrane transport; TAS:GOC.
DR   GO; GO:2001020; P:regulation of response to DNA damage stimulus; IMP:MGI.
DR   GO; GO:0034097; P:response to cytokine; IDA:MGI.
DR   InterPro; IPR013281; Apop_reg_Mc1.
DR   InterPro; IPR002475; Bcl2-like.
DR   InterPro; IPR020717; Bcl2_BH1_motif_CS.
DR   InterPro; IPR020726; Bcl2_BH2_motif_CS.
DR   InterPro; IPR020728; Bcl2_BH3_motif_CS.
DR   InterPro; IPR026298; Blc2_fam.
DR   PANTHER; PTHR11256; PTHR11256; 1.
DR   PANTHER; PTHR11256:SF6; PTHR11256:SF6; 1.
DR   Pfam; PF00452; Bcl-2; 1.
DR   PRINTS; PR01866; APOPREGMCL1.
DR   PRINTS; PR01862; BCL2FAMILY.
DR   PROSITE; PS50062; BCL2_FAMILY; 1.
DR   PROSITE; PS01080; BH1; 1.
DR   PROSITE; PS01258; BH2; 1.
DR   PROSITE; PS01259; BH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Complete proteome;
KW   Cytoplasm; Developmental protein; Differentiation;
KW   Direct protein sequencing; Isopeptide bond; Membrane; Mitochondrion;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   CHAIN         1    350       Induced myeloid leukemia cell
FT                                differentiation protein Mcl-1.
FT                                /FTId=PRO_0000143080.
FT   TRANSMEM    328    348       Helical. {ECO:0000255}.
FT   REGION      104    175       PEST-like.
FT   MOTIF       209    223       BH3.
FT   MOTIF       252    272       BH1.
FT   MOTIF       304    319       BH2.
FT   SITE        127    128       Cleavage; by caspase-3.
FT   SITE        157    158       Cleavage; by caspase-3.
FT   MOD_RES     121    121       Phosphoserine.
FT                                {ECO:0000269|PubMed:12223490}.
FT   MOD_RES     159    159       Phosphoserine; by GSK3-alpha and GSK3-
FT                                beta. {ECO:0000269|PubMed:16543145}.
FT   MOD_RES     162    162       Phosphoserine.
FT                                {ECO:0000269|PubMed:23024798}.
FT   MOD_RES     163    163       Phosphothreonine; by MAPK.
FT                                {ECO:0000269|PubMed:12223490,
FT                                ECO:0000269|PubMed:15241487,
FT                                ECO:0000269|PubMed:23024798}.
FT   CROSSLNK      5      5       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK     40     40       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK    136    136       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK    194    194       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK    197    197       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   VAR_SEQ     231    271       MLRKLDIKNEDDVKSLSRVMIHVFSDGVTNWGRIVTLISFG
FT                                -> WVCGVLPCRGPRRWHQECAAGFCRCCWSRSWFGISNKI
FT                                ALL (in isoform 2).
FT                                {ECO:0000303|PubMed:10837489}.
FT                                /FTId=VSP_000532.
FT   VAR_SEQ     272    350       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10837489}.
FT                                /FTId=VSP_000533.
FT   VARIANT     173    173       E -> D (in dbSNP:rs2737820).
FT                                {ECO:0000269|PubMed:10766760,
FT                                ECO:0000269|PubMed:7682708}.
FT                                /FTId=VAR_024021.
FT   VARIANT     227    227       A -> V (in dbSNP:rs11580946).
FT                                {ECO:0000269|PubMed:10634649,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_024022.
FT   VARIANT     231    231       M -> L. {ECO:0000269|PubMed:18987736}.
FT                                /FTId=VAR_054157.
FT   MUTAGEN       5      5       K->R: Reduced ubiquitination.
FT                                {ECO:0000269|PubMed:15989957}.
FT   MUTAGEN      40     40       K->R: Reduced ubiquitination.
FT                                {ECO:0000269|PubMed:15989957}.
FT   MUTAGEN     127    127       D->A: Abolishes formation of 28 and 17
FT                                kDa cleavage products by CASP3. Abolishes
FT                                cleavage by caspase-3; when associated
FT                                with A-157.
FT                                {ECO:0000269|PubMed:15122313}.
FT   MUTAGEN     136    136       K->R: Reduced ubiquitination.
FT                                {ECO:0000269|PubMed:15989957}.
FT   MUTAGEN     157    157       D->A: Abolishes formation of 23 and 21
FT                                kDa cleavage products by CASP3. Abolishes
FT                                cleavage by caspase-3; when associated
FT                                with A-127.
FT                                {ECO:0000269|PubMed:15122313}.
FT   MUTAGEN     159    159       S->A: Loss of phosphorylation by GSK3 and
FT                                loss of ubiquitination increasing protein
FT                                stability. {ECO:0000269|PubMed:16543145}.
FT   MUTAGEN     162    162       S->A: Abolishes mitochondrial
FT                                localization and decreases stability.
FT                                {ECO:0000269|PubMed:15241487,
FT                                ECO:0000269|PubMed:23024798}.
FT   MUTAGEN     162    162       S->A: No effect.
FT                                {ECO:0000269|PubMed:15241487,
FT                                ECO:0000269|PubMed:23024798}.
FT   MUTAGEN     163    163       T->A,E: No effect on mitochondrial
FT                                localization.
FT                                {ECO:0000269|PubMed:15241487}.
FT   MUTAGEN     163    163       T->A: Abolishes phosphorylation by MAPK.
FT                                No effect on phosphorylation induced by
FT                                okadaic acid or taxol.
FT                                {ECO:0000269|PubMed:15241487}.
FT   MUTAGEN     194    194       K->R: Reduced ubiquitination.
FT                                {ECO:0000269|PubMed:15989957}.
FT   MUTAGEN     197    197       K->R: Reduced ubiquitination.
FT                                {ECO:0000269|PubMed:15989957}.
FT   MUTAGEN     208    208       K->R: No effect on ubiquitination.
FT                                {ECO:0000269|PubMed:15989957}.
FT   MUTAGEN     234    234       K->R: No effect on ubiquitination.
FT                                {ECO:0000269|PubMed:15989957}.
FT   HELIX       173    191       {ECO:0000244|PDB:4HW4}.
FT   STRAND      200    202       {ECO:0000244|PDB:3KJ1}.
FT   HELIX       203    223       {ECO:0000244|PDB:4HW4}.
FT   HELIX       225    235       {ECO:0000244|PDB:4HW4}.
FT   HELIX       240    253       {ECO:0000244|PDB:4HW4}.
FT   HELIX       254    256       {ECO:0000244|PDB:4HW4}.
FT   HELIX       261    280       {ECO:0000244|PDB:4HW4}.
FT   HELIX       284    286       {ECO:0000244|PDB:4HW4}.
FT   HELIX       287    299       {ECO:0000244|PDB:4HW4}.
FT   TURN        300    302       {ECO:0000244|PDB:4HW4}.
FT   HELIX       303    308       {ECO:0000244|PDB:4HW4}.
FT   HELIX       311    319       {ECO:0000244|PDB:4HW4}.
SQ   SEQUENCE   350 AA;  37337 MW;  D85821AC59275F1F CRC64;
     MFGLKRNAVI GLNLYCGGAG LGAGSGGATR PGGRLLATEK EASARREIGG GEAGAVIGGS
     AGASPPSTLT PDSRRVARPP PIGAEVPDVT ATPARLLFFA PTRRAAPLEE MEAPAADAIM
     SPEEELDGYE PEPLGKRPAV LPLLELVGES GNNTSTDGSL PSTPPPAEEE EDELYRQSLE
     IISRYLREQA TGAKDTKPMG RSGATSRKAL ETLRRVGDGV QRNHETAFQG MLRKLDIKNE
     DDVKSLSRVM IHVFSDGVTN WGRIVTLISF GAFVAKHLKT INQESCIEPL AESITDVLVR
     TKRDWLVKQR GWDGFVEFFH VEDLEGGIRN VLLAFAGVAG VGAGLAYLIR
//
